All In Biotech

Drug Trial Radar · NCT06456359

Pasireotide as Maintenance Treatment in Synovial Sarcoma and Desmoplastic Small Round Cell Tumor

Pasireotide as Maintenance Treatment With Monthly Deep Intramuscular Injection in SSTR2/3/5-Expressing Synovial Sarcoma and Desmoplastic Small Round Cell Tumor

Last checked: Nov 20, 2026Latest source record: Jan 13, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

28

Planned (sponsor's estimate)

Start

Dec 19, 2024

Primary completion

Oct 2027

Study completion Oct 2028

Sponsor

Lead sponsor
University Hospital HeidelbergAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jun 13, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 13 years, up to 50 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

PAMSARC is a non-commercial interventional Phase 2 clinical trial of academic research institutions, with its primary goal being to improve medical treatment of fusion driven Desmoplastic small round cell tumor (DSRCT) and Synovial sarcoma (SySa) in young adults and adolsecents with male predominance. Current management of DSRCT and SySa includes chemotherapy, radiation and aggressive cytoreductive surgery. Despite advances in multimodal therapy, outcomes remain poor with frequent disease recurrence and very limited options for patients with advanced disease. Selected somatostatin receptor (SSTR) family members, i.e., SSTR2, SSTR3 and SSTR5, are frequently overexpressed in DSRCT and SySa, providing the rationale for treatment with somatostatin analogues (SSA). Pasireotide is a SSA with high affinity for SSTR1, -2, -3, and -5 and is approved for the treatment of Cushing's disease and acromegaly and has also shown activity in other cancers. In patients with advanced stage DSRCT and SySa, conventional chemotherapeutic approaches frequently lead to disease response, however, the duration of progression-free time after chemotherapy is short. The targeted approach with pasireotide after initial intensive multimodal treatment may have the potential to significantly improve outcome.

Conditions

  • Desmoplastic Small Round Cell Tumor
  • Synovial Sarcoma

Interventions

  • SigniforDrug

    Signifor 40 mg: each vial contains 40 mg pasireotide (as pasireotide pamoate). Signifor 60 mg: each vial contains 60 mg pasireotide (as pasireotide pamoate).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. progression-free survival (PFS)Time frame: PFS, measured from study registration to radiologically confirmed disease progression according to Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1, or death from any cause, whichever occurs first up to 4 years

Locations

4 sites in 1 country. Site status is shown where the registry gives one.

  • National Center for Tumour Diseases, University Hospital Heidelberg

    Heidelberg, Baden-Wurttemberg, Germany · Recruiting

  • Klinikum Stuttgart- Olga Hospital Zentrum für Kinder-, Jugend und Frauenmedizin

    Stuttgart, Baden-Wurttemberg, Germany · Not yet recruiting

  • Klinikum Stuttgart Studienzentrale Stuttgart Cancer Center, Tumorzentrum Eva-Mayr-Stihl

    Stuttgart, Baden-Wurttemberg, Germany · Not yet recruiting

  • Universitätsklinikum Essen Pädiatrische Hämatologie und Onkologie

    Essen, North Rhine-Westphalia, Germany · Not yet recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.